Enzyme Linked Immunosorbent Assay (ELISA) is a biochemical assay, which use antibodies and an enzyme-mediated color change to detect the presence of either antigen (proteins, peptides, and hormones) or antibody in sample. Enzyme-linked immunosorbent assay is used as diagnostic tool in medicine and analytical tool in biomedical research. ELISA analyzer is an instrument used for detecting the concentration and presence of analyte in the test sample. ELISA analyzer can be used are a part of workflow were reagents and consumables are fed to carry out ELISA and results are displayed on the screen attached to it, which is known as automated ELISA analyzer. Increasing array of products to ease the workflow is the major factor driving the ELISA analyzer market growth over the forecast period.
Moreover, increasing prevalence of infectious disease and drug development are also expected to fuel the ELISA analyzer market growth over the forecast period. However, stringent regulatory policies for product approval are expected to hinder the new product launches, which in turn is restraining growth of the market.
ELISA Analyzer Market Dynamics
New product launches with increased sophistication and value added testing environment to enhance sensitivity coupled with compactness of product are expected to fuel growth of the ELISA analyzer market over the forecast period. For instance, in 2017, Siemens Healthineers, received CE approval for Atellica Solution, an automated immunoassay and chemistry analyzers in Europe, the U.S., South America, and Asia.
The product has comprehensive menu of 170 assays, which include cardiac, thyroid, and reproductive tests. Furthermore, the company has pipeline of about 50 more assays, which are expected to be added to the present menu. In 2014, Sysmex Corporation launched HISCL-800, a compact and automated immunoassay system used for the immunochemistry testing. The product is claimed to be more compact as compared to other products of same series.
ELISA technique holds promising results in diagnosis of health related problems. High prevalence of infectious disease and cancer are propelling growth of the ELISA analyzer market. For instance, according to World Health Organization (WHO), in 2016, an estimated cases of malaria in 91 countries across the globe were around 216 million, which increased by 5 million as compared to 2015. Moreover, funding and initiatives to eradicate the disease burden are expected to increase the adoption of diagnostic assay and advanced analyzer, in turn augment the ELISA analyzer market growth.
Furthermore, increasing number of drug discovery programs by pharmaceutical and biopharmaceutical companies are propelling demands for improved and advanced instrument to ease with good quality results in less time as a part of the workflow. According to International Federation of Pharmaceutical Manufacturers & Associations, in 2015, new 56 medicines were launched, while currently more than 7,000 compounds are at different stages of development worldwide. Such drug discovery programmes prominently use ELISA in the clinical trial, in turn increasing adoption of ELISA analyzer.
ELISA Analyzer Market - Regional Analysis
Regional segmentation of the market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America ELISA analyzer market holds dominant position in global market, owing to increasing burden of infectious disease, adoption of immunoassays in diagnosis, and presence of local market players. For instance, according to National Ambulatory Medical Care Survey, 2015, in the U.S. around 16.8 million visits were reported to physician offices for infectious and parasitic diseases.
However, Asia Pacific ELISA analyzer market is expected to witness rapid growth, owing to increasing demand from emerging economies such as India, where large patient population demands for rapid and high-throughput technology for test and detection of disease.
ELISA Analyzer Market – Competitive Analysis
Key players operating in the ELISA analyzer market include Siemens Healthineers, Awareness Technology, Inc., Dynes Technologies, Inc., EUROIMMUN AG, Robimes, Gold Standard Diagnostics, Corp., BioTek Instruments, Inc., and Berthold Technologies GmbH & Co. KG.
In 2016, Gold Standard Diagnostics, Corp. and R-BioPharma AG collaborated on multiple technology and marketing initiatives to leverages respective strength of both companies to expand product offering and geographic sales coverage. In 2013, Gold Standard Diagnostics, Corp. established distribution partnership for the ThunderBolt automated immunoassay analyzer in 18 countries since its launch in 2012.
- In August 2019, PerkinElmer, Inc., launched EUROIMMUN Aspergillus Antigen ELISA for detection of aspergillus infections.
- In 2017, Siemens Healthineers, received CE mark for Atellica Solution, which is an automated immunoassay and chemistry analyzer and are available in the U.S., Europe, South America, and Asian markets.
- In 2014, Sysmex Corporation launched HISCL-800, a compact and automated immunoassay system used for the immunochemistry testing.
- In 2012, Dynex Technologies Inc., received china state food and drug administration (SFDA) approval for its DS2 automated enzyme-linked immunosorbent assay (ELISA) analyzer in China. This DS2 assay is considered to be an automated ELISA processing system for clinical diagnostic assays.
- In 2012, Gold Standard Diagnostics, Corp. (GSD) launched fully automated ELISA platform thunderbolt
ELISA Analyzer Market Taxonomy
Based on mode of operation:
Based on application:
- Vaccines Development
- Drug Monitoring and Pharmaceutical Industry
Based on modality:
Based on end user:
- Clinical Research Organizations
- Pharmaceutical and Biotechnology Companies
- Educational and Research Institutes
- Diagnostic Laboratories
Based on region:
- North America
- Latin America
- Asia Pacific
- Middle East